This a renewal application for a multidisciplinary training program in tumor immunology. The program will continue to provide training in all aspects of tumor immunology research. The program proposes to continue to support a total of nine trainees (3 pre-doctoral and 6 post-doctoral trainees) in a highly structured research training experience under the supervision of experienced faculty mentors. Over the past 30 years the UCLA Tumor Immunology Training Program has served as a major campus facilitator for bridging training in the fields of cancer and immunology and is the sole comprehensive UCLA campus training program integrating concerns of fundamental molecular life scientists with those of clinical oncologists. During the past 5 years, the Tumor Immunology Training Program has remained vital and advanced its importance in the UCLA academic community through the recruitment of new faculty members from different departments into the training program. In addition, the program has facilitated UCLA's internationally recognized standing as a major center in clinical trials utilizing immunotherapy and genetic immunotherapy against a variety of cancers. The training program has been highly successful in developing academic investigators;the majority of trainees are continuing in research careers. Thus, our training program continues as a strong component of basic, translational and clinical investigations in tumor immunology at UCLA. These unique, interactive and highly integrated activities in tumor immunology serve as an outstanding resource for our trainees.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Institutional National Research Service Award (T32)
Project #
5T32CA009120-35
Application #
7916634
Study Section
Special Emphasis Panel (ZCA1-RTRB-R (O1))
Program Officer
Lim, Susan E
Project Start
1980-07-01
Project End
2012-04-22
Budget Start
2010-09-01
Budget End
2012-04-22
Support Year
35
Fiscal Year
2010
Total Cost
$411,595
Indirect Cost
Name
University of California Los Angeles
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
092530369
City
Los Angeles
State
CA
Country
United States
Zip Code
90095
Salehi, Sahar; Sosa, Rebecca A; Jin, Yi-Ping et al. (2018) Outside-in HLA class I signaling regulates ICAM-1 clustering and endothelial cell-monocyte interactions via mTOR in transplant antibody-mediated rejection. Am J Transplant 18:1096-1109
Patananan, Alexander N; Sercel, Alexander J; Teitell, Michael A (2018) More than a powerplant: the influence of mitochondrial transfer on the epigenome. Curr Opin Physiol 3:16-24
Tsoi, Jennifer; Robert, Lidia; Paraiso, Kim et al. (2018) Multi-stage Differentiation Defines Melanoma Subtypes with Differential Vulnerability to Drug-Induced Iron-Dependent Oxidative Stress. Cancer Cell 33:890-904.e5
Grasso, Catherine S; Giannakis, Marios; Wells, Daniel K et al. (2018) Genetic Mechanisms of Immune Evasion in Colorectal Cancer. Cancer Discov 8:730-749
Katagiri, Yasuhiro; Morgan, Ashlea A; Yu, Panpan et al. (2018) Identification of novel binding sites for heparin in receptor protein-tyrosine phosphatase (RPTP?): Implications for proteoglycan signaling. J Biol Chem 293:11639-11647
Nakamura, Kojiro; Kageyama, Shoichi; Yue, Shi et al. (2018) Heme oxygenase-1 regulates sirtuin-1-autophagy pathway in liver transplantation: From mouse to human. Am J Transplant 18:1110-1121
Kageyama, Shoichi; Nakamura, Kojiro; Fujii, Takehiro et al. (2018) Recombinant relaxin protects liver transplants from ischemia damage by hepatocyte glucocorticoid receptor: From bench-to-bedside. Hepatology 68:258-273
By the Contributors to the C4 Article (Appendix 1) (2018) Current opinions in organ allocation. Am J Transplant 18:2625-2634
Sosa, Rebecca A; Rossetti, Maura; Naini, Bita V et al. (2018) Pattern Recognition Receptor-reactivity Screening of Liver Transplant Patients: Potential for Personalized and Precise Organ Matching to Reduce Risks of Ischemia-reperfusion Injury. Ann Surg :
Lu, Jianqin; Liu, Xiangsheng; Liao, Yu-Pei et al. (2018) Breast Cancer Chemo-immunotherapy through Liposomal Delivery of an Immunogenic Cell Death Stimulus Plus Interference in the IDO-1 Pathway. ACS Nano 12:11041-11061

Showing the most recent 10 out of 144 publications